此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RGX-314 在脉络膜上腔对糖尿病视网膜病变参与者的长期随访研究

2026年11月5日 更新者:AbbVie

一项长期随访研究,以评估脉络膜上腔给药 RGX-314 治疗无中心受累的糖尿病性视网膜病变-糖尿病性黄斑水肿的安全性和有效性

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.

研究概览

研究类型

介入性

注册 (实际的)

103

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85014
        • Retinal Research Institute, LLC
    • California
      • Bakersfield、California、美国、93309
        • California Retina Consultants
      • Beverly Hills、California、美国、90211
        • Retina-Vitreous Associates Medical Group
      • Los Angeles、California、美国、90017
        • Retinal Diagnostic Center
      • Mountain View、California、美国、94040
        • Northern California Retina Vitreous Associates Medical Group Inc
      • Pasadena、California、美国、91107
        • California Eye Specialists Medical Group, Inc
      • Poway、California、美国、92064
        • Retina Consultants San Diego
      • Santa Barbara、California、美国、93103
        • California Retina Consultants CRC
    • Georgia
      • Augusta、Georgia、美国、30909
        • Southeast Retina Center, PC
    • Illinois
      • Oak Forest、Illinois、美国、60452
        • University Retina and Macula Associates, PC
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • Cumberland Valley Retina Consultants
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Ophthalmic Consultants of Boston
    • Nevada
      • Reno、Nevada、美国、89502
        • Sierra eye Associates
    • New Jersey
      • Teaneck、New Jersey、美国、07666
        • New Jersey Retina
    • New Mexico
      • Albuquerque、New Mexico、美国、87109
        • Vision Research Center Eye Associates of New Mexico
    • North Carolina
      • Durham、North Carolina、美国、27705
        • Duke University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Mid Atlantic Retina
    • Tennessee
      • Germantown、Tennessee、美国、38138
        • Charles Retina Institute, P.C
    • Texas
      • Austin、Texas、美国、78750
        • Austin Clinical Research
      • The Woodlands、Texas、美国、77384
        • Retina Consultants of Texas

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Must provide written, signed informed consent for this study
  • Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
  • Must be willing and able to comply with all study procedures

Exclusion Criteria:

  • None

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Standard of Care

Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration.

Standard of Care

其他:Supplemental Treatment

DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye.

Standard of Care

Injection

其他名称:
  • 艾莉亚

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
大体时间:5 years inclusive of the parent study

To evaluate the long-term safety of ABBV-RGX-314

5 years inclusive of the parent study

次要结果测量

结果测量
大体时间
需要对眼部糖尿病并发症进行任何额外干预的参与者比例(例如,抗 VEGF 玻璃体内注射或 PRP)
大体时间:5 年,包括家长学习
5 年,包括家长学习
患有任何威胁视力的眼部糖尿病并发症的参与者比例
大体时间:5 年,包括家长学习
5 年,包括家长学习
Incidences of non-ocular AEs and any Adverse Events of Special Interest
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
大体时间:5 years, inclusive of the parent study
5 years, inclusive of the parent study
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of retina specialist visits attended for complications of DR based on chart review
大体时间:5 years, inclusive to the parent study
5 years, inclusive to the parent study

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年4月4日

初级完成 (估计的)

2031年6月1日

研究完成 (估计的)

2031年6月1日

研究注册日期

首次提交

2022年3月16日

首先提交符合 QC 标准的

2022年3月16日

首次发布 (实际的)

2022年3月25日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD 共享时间框架

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD 共享访问标准

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅